Veterinary Antimicrobial Susceptibility Testing Market - Global Forecast 2025-2032

Veterinary antimicrobial susceptibility testing is rapidly evolving, empowering stakeholders to address resistance risks and improve diagnostic outcomes in both companion animals and production species. This report provides a concise, actionable overview of market dynamics, key technologies, and strategic imperatives for decision-makers.

Market Snapshot: Veterinary Antimicrobial Susceptibility Testing Market Overview

The veterinary antimicrobial susceptibility testing market grew from USD 113.38 million in 2024 to USD 123.33 million in 2025. It is set to increase further at a CAGR of 8.75%, reaching USD 221.88 million by 2032. Driven by advances in automation and molecular diagnostics, the market balances clinical demand and regulatory changes while responding to zoonotic threats and industry cost pressures.

Scope & Segmentation

• Test Types: Includes automated systems such as MicroScan, PHOENIX, VITEK, WalkAway; broth microdilution (automated and manual); disk diffusion; Etest; molecular methods (LAMP, next-generation sequencing, PCR, qPCR).
• Animal Types: Focus spans aquaculture, companion animals, equine, livestock, and poultry, reflecting distinct diagnostic and clinical priorities.
• End Users: Stakeholders comprise pharmaceutical and biotechnology companies, research institutes, veterinary diagnostic laboratories, and veterinary hospitals and clinics.
• Pathogen Types: Testing encompasses fungi, gram-negative and gram-positive bacteria, and mycobacteria—each requiring tailored protocols.
• Sample Types: Blood, milk, swab, tissue, and urine are common matrices, presenting varied workflow and analytical demands.
• Product Types: Offerings range from automated and bench-top instruments, to consumables, reagents, as well as software and services including data management and technical support.
• Geographical Coverage: Regions assessed include the Americas (United States, Canada, Mexico, Brazil, Argentina, and others), Europe, Middle East & Africa (UK, Germany, France, Middle Eastern countries, African nations), and Asia-Pacific (China, India, Japan, Australia, and Southeast Asian countries).
• Key Companies: Evaluated entities include Thermo Fisher Scientific Inc., bioMérieux SA, Becton, Dickinson and Company, IDEXX Laboratories, Inc., Bruker Corporation, Creative Diagnostics, Merck & Co., Inc., Eurofins Scientific SE, SGS SA, and Bio-Rad Laboratories.

Key Takeaways

• Adoption of automation and next-generation sequencing is transforming laboratory workflows, enabling faster detection of antimicrobial resistance and supporting precision treatment pathways.
• Increasing regulatory oversight and requirements for antimicrobial stewardship are compelling organizations to modernize testing protocols and elevate reporting standards for animal health and food safety.
• Strategic partnerships between industry players, including instrument and software vendors, are fostering ecosystem solutions that address operational challenges and support data-driven decision-making.
• Collaboration among laboratories, academic institutions, and industry stakeholders is promoting the aggregation of susceptibility data to inform regional guidelines and support public health objectives.
• Customized diagnostic approaches and investment in workforce training are essential for addressing the diverse testing needs across animal species, regions, and clinical scenarios.

Tariff Impact

The introduction of U.S. tariffs on imported diagnostic reagents and instruments in 2025 is adding cost complexity for market participants. Procurement strategies are shifting with more emphasis on local supplier relationships, in-house reagent production, and workflow efficiency to balance service rates and profit margins. These measures are reshaping collaborations between global manufacturers and regional distributors, boosting the resilience of supply chains and supporting continued market growth.

Methodology & Data Sources

This report is based on a rigorous blend of secondary research, including industry publications, regulatory guidelines, patents, and company information, complemented by structured interviews with laboratory managers, regulatory experts, R&D executives, and veterinary clinicians. Cross-verification and scenario analysis ensure the integrity and relevance of market findings.

Why This Report Matters

• Enables leadership teams to benchmark market entry and technology investment strategies aligned with regulatory trends and clinical needs.
• Supports procurement, operations, and R&D leaders in identifying key growth opportunities, navigating region-specific challenges, and developing sustainable partnerships.
• Provides insight into the role of automation, molecular diagnostics, and digital platforms in advancing laboratory capabilities and compliance.

Conclusion

This analysis equips decision-makers with actionable intelligence to drive innovation, support compliance, and optimize outcomes in veterinary antimicrobial susceptibility testing. Organizations can leverage these insights to navigate dynamic market forces and position for sustained growth.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.